- Home
- SKT vs AXSM Comparison
SKT vs AXSM Comparison
Compare SKT & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKT
- AXSM
- Stock Information
- Founded
- SKT 1981
- AXSM 2012
- Country
- SKT United States
- AXSM United States
- Employees
- SKT N/A
- AXSM N/A
- Industry
- SKT Real Estate Investment Trusts
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- SKT Real Estate
- AXSM Health Care
- Exchange
- SKT Nasdaq
- AXSM Nasdaq
- Market Cap
- SKT 3.8B
- AXSM 4.2B
- IPO Year
- SKT 1993
- AXSM 2015
- Fundamental
- Price
- SKT $35.82
- AXSM $137.75
- Analyst Decision
- SKT Buy
- AXSM Strong Buy
- Analyst Count
- SKT 9
- AXSM 14
- Target Price
- SKT $35.11
- AXSM $158.93
- AVG Volume (30 Days)
- SKT 757.7K
- AXSM 1.2M
- Earning Date
- SKT 02-19-2025
- AXSM 02-18-2025
- Dividend Yield
- SKT 3.07%
- AXSM N/A
- EPS Growth
- SKT N/A
- AXSM N/A
- EPS
- SKT 0.88
- AXSM N/A
- Revenue
- SKT $537,352,000.00
- AXSM $385,693,000.00
- Revenue This Year
- SKT N/A
- AXSM $45.18
- Revenue Next Year
- SKT $3.99
- AXSM $65.22
- P/E Ratio
- SKT $40.69
- AXSM N/A
- Revenue Growth
- SKT 13.69
- AXSM 42.53
- 52 Week Low
- SKT $25.94
- AXSM $64.11
- 52 Week High
- SKT $37.57
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- SKT 66.01
- AXSM 74.55
- Support Level
- SKT $34.17
- AXSM $124.04
- Resistance Level
- SKT $36.76
- AXSM $130.52
- Average True Range (ATR)
- SKT 0.85
- AXSM 5.78
- MACD
- SKT 0.30
- AXSM 1.11
- Stochastic Oscillator
- SKT 78.49
- AXSM 96.07
About SKT Tanger Inc.
Tanger Inc is a leading owner and operator of outlet and open-air retail shopping destinations. Tanger's portfolio of 38 outlet centers and one open-air lifestyle center comprises over 15 million square feet well positioned across tourist destinations and vibrant markets in U.S. states and Canada.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.